ID   AG876
AC   CVCL_A422
SY   Ag876; AG-876; Ag-876; AG 876; AG-876 BL; AG876BL
DR   Cosmic; 931115
DR   Wikidata; Q54748628
RX   PubMed=205793;
RX   PubMed=2052620;
RX   PubMed=3026973;
RX   PubMed=6243721;
RX   PubMed=6243722;
RX   PubMed=6265077;
RX   PubMed=6286763;
RX   PubMed=8220424;
RX   PubMed=8344493;
RX   PubMed=8515068;
RX   PubMed=9192833;
RX   PubMed=9473234;
RX   PubMed=9563901;
RX   PubMed=12133989;
RX   PubMed=16490228;
RX   PubMed=24590883;
CC   Population: African; Ghanaian.
CC   Virology: Contains a complete EBV genome (strain AG876) which has been sequenced (PubMed=16490228).
CC   Doubling time: 21 hours (PubMed=8402660).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Spleen; UBERON=UBERON_0002106.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   8Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 10-04-25; Version: 19
//
RX   PubMed=205793; DOI=10.1038/272629a0;
RA   Pizzo P.A., Magrath I.T., Chattopadhyay S.K., Biggar R.J., Gerber P.;
RT   "A new tumour-derived transforming strain of Epstein-Barr virus.";
RL   Nature 272:629-631(1978).
//
RX   PubMed=2052620; DOI=10.1073/pnas.88.12.5413; PMCID=PMC51883;
RA   Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A.,
RA   Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.;
RT   "p53 mutations in human lymphoid malignancies: association with
RT   Burkitt lymphoma and chronic lymphocytic leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991).
//
RX   PubMed=3026973; DOI=10.1002/ijc.2910390215;
RA   Ehlin-Henriksson B., Manneborg-Sandlund A., Klein G.;
RT   "Expression of B-cell-specific markers in different Burkitt lymphoma
RT   subgroups.";
RL   Int. J. Cancer 39:211-218(1987).
//
RX   PubMed=6243721; DOI=10.1093/jnci/64.3.465;
RA   Magrath I.T., Pizzo P.A., Whang-Peng J., Douglass E.C., Alabaster O.,
RA   Gerber P., Freeman C.B., Novikovs L.;
RT   "Characterization of lymphoma-derived cell lines: comparison of cell
RT   lines positive and negative for Epstein-Barr virus nuclear antigen. I.
RT   Physical, cytogenetic, and growth characteristics.";
RL   J. Natl. Cancer Inst. 64:465-476(1980).
//
RX   PubMed=6243722; DOI=10.1093/jnci/64.3.477;
RA   Magrath I.T., Freeman C.B., Pizzo P.A., Gadek J., Jaffe E.S.,
RA   Santaella M., Hammer C., Frank M.M., Reaman G., Novikovs L.;
RT   "Characterization of lymphoma-derived cell lines: comparison of cell
RT   lines positive and negative for Epstein-Barr virus nuclear antigen.
RT   II. Surface markers.";
RL   J. Natl. Cancer Inst. 64:477-483(1980).
//
RX   PubMed=6265077;
RA   Pizzo P.A., Chattopadhyay S.K., Magrath I.T., Del Giacco E.,
RA   Sherrick D., Gray T.E.;
RT   "Examination of Epstein-Barr virus and C-type proviral sequences in
RT   American and African lymphomas and derivative cell lines.";
RL   Cancer Res. 41:3165-3171(1981).
//
RX   PubMed=6286763; DOI=10.4049/jimmunol.129.3.1336;
RA   Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd-Kulikowsk H.D.,
RA   Parsons R.G.;
RT   "Immunoglobulin secretion by cell lines derived from African and
RT   American undifferentiated lymphomas of Burkitt's and non-Burkitt's
RT   type.";
RL   J. Immunol. 129:1336-1342(1982).
//
RX   PubMed=8220424; DOI=10.1038/ng0993-56;
RA   Bhatia K.G., Huppi K., Spangler G., Siwarski D., Iyer R., Magrath I.T.;
RT   "Point mutations in the c-Myc transactivation domain are common in
RT   Burkitt's lymphoma and mouse plasmacytomas.";
RL   Nat. Genet. 5:56-61(1993).
//
RX   PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493;
RA   Bhatia K.G., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R.,
RA   Magrath I.T.;
RT   "Hemi- or homozygosity: a requirement for some but not other p53
RT   mutant proteins to accumulate and exert a pathogenetic effect.";
RL   FASEB J. 7:951-956(1993).
//
RX   PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418;
RA   Jain V.K., Judde J.-G., Max E.E., Magrath I.T.;
RT   "Variable IgH chain enhancer activity in Burkitt's lymphomas suggests
RT   an additional, direct mechanism of c-myc deregulation.";
RL   J. Immunol. 150:5418-5428(1993).
//
RX   PubMed=9192833;
RA   Cherney B.W., Bhatia K.G., Sgadari C., Gutierrez M.I., Mostowski H.S.,
RA   Pike S.E., Gupta G., Magrath I.T., Tosato G.;
RT   "Role of the p53 tumor suppressor gene in the tumorigenicity of
RT   Burkitt's lymphoma cells.";
RL   Cancer Res. 57:2508-2515(1997).
//
RX   PubMed=9473234; DOI=10.1182/blood.V91.5.1680;
RA   Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.;
RT   "p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a
RT   mRNA and protein expression in Burkitt's lymphoma.";
RL   Blood 91:1680-1687(1998).
//
RX   PubMed=9563901;
RA   Fan S.-J., Cherney B.W., Reinhold W.C., Rucker K., O'Connor P.M.;
RT   "Disruption of p53 function in immortalized human cells does not
RT   affect survival or apoptosis after taxol or vincristine treatment.";
RL   Clin. Cancer Res. 4:1047-1054(1998).
//
RX   PubMed=12133989; DOI=10.4049/jimmunol.169.3.1593;
RA   Paludan C., Bickham K., Nikiforow S., Tsang M.L., Goodman K.,
RA   Hanekom W.A., Fonteneau J.-F., Stevanovic S., Munz C.;
RT   "Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill
RT   Burkitt's lymphoma cells.";
RL   J. Immunol. 169:1593-1603(2002).
//
RX   PubMed=16490228; DOI=10.1016/j.virol.2006.01.015;
RA   Dolan A., Addison C., Gatherer D., Davison A.J., McGeoch D.J.;
RT   "The genome of Epstein-Barr virus type 2 strain AG876.";
RL   Virology 350:164-170(2006).
//
RX   PubMed=24590883; DOI=10.1002/gcc.22161;
RA   Murga Penas E.-M., Schilling G., Behrmann P., Klokow M.,
RA   Vettorazzi E., Bokemeyer C., Dierlamm J.;
RT   "Comprehensive cytogenetic and molecular cytogenetic analysis of 44
RT   Burkitt lymphoma cell lines: secondary chromosomal changes
RT   characterization, karyotypic evolution, and comparison with primary
RT   samples.";
RL   Genes Chromosomes Cancer 53:497-515(2014).
//